[Asynchronous left ventricular filling in patients with angina pectoris: assessment by multiple gated blood pool imaging].

T. Yamagishi,M. Ozaki,T. Ikezono,T. Shimizu,Y. Furutani,H. Ogawa,Y. Matsuda,T. Kumada,R. Kusukawa,K. Nishiue

1983-11-01

Abstract:

What problem does this paper attempt to address?

[The benefit of pars plana vitrectomy for the resolution of complications of proliferative diabetic retinopathy].

O. Chrapek,B. Jirková,J. Šimičák,M. Šín,J. Řehák

2013-03-01

Abstract:Between 1997 and 2007, we have conducted eye surgery on 72 patients (i.e. 72 eyes) as a consequence of proliferative diabetic retinopathy complications. The patients' average age was 61; the follow-up observations were carried out over a period of one year after the surgery. When we compare the initial vision with the visual acuity measured during the last follow-up examination in the late post-operative period, i.e. one year after the surgery, we can conclude that the vision of46 eyes (63%) had improved, 17 eyes (24%) did not show any change in vision, and the vision of nine eyes (13%) had deteriorated. Visual acuity of 1/60 (metric system) or better was found in 55 eyes (76%) during the late post-operative period; 6/60 vision or better was found in 29 eyes (40%), and four eyes (6%) showed 6/12 vision or better. If we compare the vision in the early post-operative period with the visual acuity during the last follow-up examination in the late post-operative period, we can conclude that in most cases, i.e. in 45 eyes (62.5%), the vision did not change any further during the months after the surgery, and one eye (1.5%) even showed improvement in visual acuity. It was confirmed that a positive result of pars plana vitrectomy observed in the early post-operative period may indeed persist even during the following months and years of the patient's life.
Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study

Gaetano Pezzicoli,Francesco Salonne,Vittoria Musci,Federica Ciciriello,Stefania Tommasi,Rosanna Lacalamita,Alfredo Zito,Sara Antonia Allegretta,Antonio Giovanni Solimando,Mimma Rizzo

DOI: https://doi.org/10.3390/jcm12247761

2023-12-18

Abstract:Metastatic upper tract urothelial carcinoma (mUTUC) has a poor prognosis. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in patients with metastatic urothelial carcinoma. However, data supporting the use of ICIs in patients with mUTUC are limited. A promising synergy between ICI and concomitant radiotherapy (RT) has been reported in patients with mUTUC. Our research involved a case-based investigation and emphasized the successful integration of different specialists' skills. Observed after partial urethrectomy procedures for muscle-invasive upper tract urothelial carcinoma (UTUC), the radiological detection of lung metastases prompted us to implement cisplatin-based first-line chemotherapy and molecular characterization in the treatment process. We uncovered alterations in the ERBB2 and FGFR3 genes and mismatch repair deficiency at a molecular level. First-line chemotherapy treatment led to a stable disease, and the patient was started on maintenance immunotherapy with Avelumab. Subsequently, an increase in the size of the lung nodules was described, and the patient received radiotherapy for three lung lesions in combination with immunotherapy. After 3 months, a restaging CT scan reported a complete response, which is still ongoing. We discuss the mechanisms driving RT/ICI synergy and the molecular profile of mUTUC as factors that should be considered in therapeutic strategy planning. Molecular insight enhances the originality of our study, providing a nuanced understanding of the genetic landscape of mUTUC and paving the way for targeted therapeutic strategies. The therapeutic armamentarium expansion encourages the design of a multimodal and personalized approach for each mUTUC patient, taking into account tumor heterogeneity and molecular profiling.
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Veronica Mollica,Alessandro Rizzo,Rodolfo Montironi,Liang Cheng,Francesca Giunchi,Riccardo Schiavina,Matteo Santoni,Michelangelo Fiorentino,Antonio Lopez-Beltran,Eugenio Brunocilla,Giovanni Brandi,Francesco Massari

DOI: https://doi.org/10.3390/cancers12061449

2020-06-02

Abstract:Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunotherapeutic approaches in UC therapy, where immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and pathways as new potential targets in metastatic UC. In this review, we will discuss the recent advances and highlight future directions of the medical treatment of UC, with a particular focus on recently published data and ongoing active and recruiting trials.
The evolving treatment landscape of metastatic urothelial cancer

Giandomenico Roviello,Matteo Santoni,Guru P. Sonpavde,Martina Catalano

DOI: https://doi.org/10.1038/s41585-024-00872-0

2024-05-04

Nature Reviews Urology

Abstract:Cisplatin-based chemotherapy is currently the first-line standard of care for patients with metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for cisplatin, necessitating alternative treatment options. Immune checkpoint inhibitors have been shown to be effective in cisplatin-ineligible patients. However, despite advances in the first-line setting, the prognosis remains poor, and challenges persist in selecting optimal therapies, treatment sequences and combination regimens. Maintenance therapy with avelumab revealed improved overall (OS) and progression-free survival (PFS) compared with best supportive care alone in patients with platinum-responsive mUC. Antibody–drug conjugates and targeted therapy with fibroblast growth factor receptor (FGFR) inhibitors have shown promise in selected patients, particularly in patients with metastatic disease that has progressed despite platinum-based chemotherapy. At the European Society of Medical Oncology Congress in 2023, groundbreaking results were presented from two phase III trials, EV-302/KEYNOTE-A39 and CheckMate 901, focusing on previously untreated mUC. In the former, the combination of enfortumab vedotin and pembrolizumab showed significant improvements in OS, PFS and overall response rate compared with chemotherapy alone; the combination of nivolumab with gemcitabine–cisplatin chemotherapy demonstrated a significant extension in median OS, PFS and overall response rate compared with chemotherapy alone. In addition, erdafitinib therapy resulted in significantly longer OS than chemotherapy among patients with mUC and FGFR alterations after previous treatment with immune checkpoint inhibitors. This comprehensive summary of the current treatment landscape for mUC incorporates clinical trial evidence and discussion of agents that are currently under investigation to provide support for clinical decision making and understanding of future therapeutic approaches.

urology & nephrology
CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients

L. Renders,M. Frisman,M. Ufer,I. Mosyagin,S. Haenisch,U. Ott,A. Caliebe,M. Dechant,F. Braun,U. Kunzendorf,I. Cascorbi

DOI: https://doi.org/10.1038/sj.clpt.6100039

2007-02-01

Clinical pharmacology and therapy

Abstract:
Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).

Charlotte Stahlfeld,Hamid Emamekhoo,Katherine Kaufmann,Petros Grivas,Moshe Chaim Ornstein,Iris Yeong- Fung Sheng,Caroline Burkey,Jamie Sperger,Rory M. Bade,Jennifer L. Schehr,Amy K Taylor,Yue Shi,Shuang Zhao,Joshua Michael Lang

DOI: https://doi.org/10.1200/jco.2023.41.6_suppl.547

IF: 45.3

2023-02-20

Journal of Clinical Oncology

Abstract:547 Background: Despite recent therapeutic advancements for patients with mUC, including checkpoint inhibitors (CPIs), anti-FGFR and antibody-drug conjugates (ADCs), biomarker data to predict therapeutic response and identify mechanisms of resistance remain limited. Ongoing randomized clinical trials evaluating the combination of CPIs and ADCs in these pts underscore the need to develop biomarkers to better understand who might best respond to these therapies. Here, we employ a liquid biopsy approach to molecularly characterize circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), including those isolated with Trop-2, the target of the novel drug Sacituzumab Govitecan and Datopotamab Deruxtecan. Methods: 104 blood samples serially collected from pts being treated for mUC were used for CTC collection using anti-EpCAM and Trop-2 antibodies in parallel. CTCs were isolated and stained for immune markers PD-L1 and HLA I using the VERSA (Versatile Exclusion-based Rare Sample Analysis) platform. Plasma was isolated for paired analysis of CTC and ctDNA content. CTCs were analyzed for enumeration and single-cell protein analysis. Overall survival (OS) was defined from time of sample collection, and survival analyses were performed using the Kaplan-Meier method. Results: We observed significantly shorter OS in pts with higher CTC burden (≥ 20 CTCs/7.5 mL blood) in samples captured with either EpCAM (median 34.1 vs 3.1 mo, P < 0.01) or Trop-2 (median 34.1 vs 6.2 months, P < 0.01). Furthermore, EpCAM and Trop-2 CTC burdens were higher at progression timepoints relative to responding or stable timepoints, when stratified according to treatment modality (table). Inter and intra-patient heterogeneous PD-L1 and HLA I expression and co-expression was observed on CTCs although no significant differences were seen globally between EpCAM and Trop-2 CTCs. In a cohort of pts treated with CPIs, we observed dynamic phenotypic changes in the ratio of HLA:PD-L1 that differed between EpCAM and Trop-2 CTCs. ctDNA analysis identified concordant increases in tumor fraction and acquired genomic mutations. When examined longitudinally across individual pts, these findings in tandem with changes in enumeration, suggest the emergence of different CTC subpopulations that may serve as biomarkers of resistance. Conclusions: We identify the prognostic significance of CTC enumeration with parallel EpCAM and Trop-2 CTC isolation and demonstrate the utility of a liquid biopsy assay that can detect pharmacodynamic changes in CTC burden and immune marker expression throughout the course of treatment. [Table: see text]

oncology
[Modifications in cutaneous flora following chloramphenicol therapy].

L. Váczi,R. Szanto,A. Csillag

1955-03-27

Orvosi Hetilap

Abstract:
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

Nikhil Pramod,Vladimir Makarov,Scott Dawsey,Paul G. Pavicic,Ubenthira Patgunarajah,Monica Nair,Moshe Chaim Ornstein,Timothy D. Gilligan,Christopher Eing Wee,Amanda Nizam,Omar Y. Mian,Jane Nguyen,C. Marcela Diaz-Montero,Shilpa Gupta

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.670

IF: 45.3

2024-01-31

Journal of Clinical Oncology

Abstract:670 Background: Response rates with ICI are only about 20% in mUC and we lack validated biomarkers to select patients who are most likely to derive benefit from ICI. Programmed cell death ligand 1 (PD-L1) has not proven to be a useful biomarker. We need biomarkers of response and resistance to avoid nonbeneficial treatment (Tx) and spare the majority of pts who will not respond to ICI both physical and financial toxicity. Here we report tumor genomic correlates of response and resistance to ICI in pts with mUC. Methods: We identified 335 adult pts with mUC at the Cleveland Clinic treated who received > / = 2 cycles of ICI with pembrolizumab (P) or atezolizumab (A) between 2015 and 2023. Of the 335 pts, 49 had pre-Tx archival formalin fixed paraffin-embedded (FFPE) tissues available. Pts were categorized by their response to ICI as responders (R) (Complete Response (CR), Partial Response (PR), and Stable Disease (SD)) (N = 23) or non-responders (NR) (Progressive Disease (PD)) (N = 26). Whole exome sequencing was performed from macro dissected tumors. Raw data in FASTQ format was aligned to GRCh38 human reference genome, somatic mutations were called by Mutect2 (part of GATK4) and allele-specific copy-number analysis was performed by applying the Facets and Gistic2 package. Results: Comparison of our cohort Tumor Mutation Burden (TMB) with mutation burden of 33 the cancer genome atlas (TCGA) cohorts shows close similarity to TCGA bladder urothelial carcinoma (BCLA). Median TMB in our cohort was 6.46 muts/Mb. In our cohort, TP53 hotspot mutations were found in 52% of the (R) cohort compared to 31% in the (NR) cohort. Additionally, mutations in KMT2C and KMT2A were found in 26% and 22% of the (R) cohort compared to 8% and 12 % of the (NR) cohort. (R) also had increased mutations in the ARID1A (17% vs 4%) and ERBB2 (17% vs 4%) compared to (NR). FGFR3 missense mutations were seen in only 4% of (R) cohort compared to 15% in (NR). In our complete cohort, 49% of patients had ERBB2 copy number amplifications and 92% of patient had CREBP2 deletions. Conclusions: In our real-world cohort of mUC pts treated with ICI, we identified differential genomic alterations between (R) and (NR). High frequency of ERBB2 mutations and alterations in overall cohort and higher frequency in (R) suggests potential role for anti-HER2 therapies alone or in combination with ICI. Ongoing genomic and immunologic correlative studies in our cohort will further help understand biomarkers of response and resistance to ICI in pts with mUC.

oncology
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma

Aditya Eturi,Amman Bhasin,Kevin K. Zarrabi,William J. Tester

DOI: https://doi.org/10.3390/molecules29081896

IF: 4.6

2024-04-23

Molecules

Abstract:Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease which is associated with a 10–15% 5-year survival rate and poor overall prognosis. Muscle-invasive bladder cancer (MIBC) is associated with about 50% 5 year survival when treated by radical cystectomy or trimodality therapy; stage IV disease is associated with 10–15% 5 year survival. Current therapeutic modalities for MIBC include neoadjuvant chemotherapy, surgery and/or chemoradiation, although patients with relapsed or refractory disease have a poor prognosis. However, the rapid success of immuno-oncology in various hematologic and solid malignancies offers new targets with tremendous therapeutic potential in UC. Historically, there were no predictive biomarkers to guide the clinical management and treatment of UC, and biomarker development was an unmet need. However, recent and ongoing clinical trials have identified several promising tumor biomarkers that have the potential to serve as predictive or prognostic tools in UC. This review provides a comprehensive summary of emerging biomarkers and molecular tumor targets including programmed death ligand 1 (PD-L1), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor (FGFR), DNA damage response and repair (DDR) mutations, poly (ADP-ribose) polymerase (PARP) expression and circulating tumor DNA (ctDNA), as well as their clinical utility in UC. We also evaluate recent advancements in precision oncology in UC, while illustrating limiting factors and challenges related to the clinical application of these biomarkers in clinical practice.

chemistry, multidisciplinary,biochemistry & molecular biology
Patterns of differentiation between human local populations.

N. Jardine

DOI: https://doi.org/10.1098/RSTB.1971.0108

1971-10-01

Abstract:Quantitative methods for describing infraspecific differentiation are introduced and applied to three questions about the nature of human differentiation. The first question is whether or not human local populations are differentiated consistently by different attributes; the second is whether or not human local populations are differentiated into geographical races; the third is whether or not human local populations show clinal differentiation. The anthropometric data used were published by Mahalanobis, Majumdar & Rao (1949), and Hiernaux (1956).
Management of metastatic bladder cancer

Rosa Nadal,Joaquim Bellmunt

DOI: https://doi.org/10.1016/j.ctrv.2019.04.002

Abstract:Important advances in the understanding of the biology and mechanisms of tumor progression of urothelial carcinoma (UC) have been achieved over the past decade. The treatment landscape for advanced-stage, unresectable or metastatic UC has shifted dramatically over a short period of time, with 6 new therapeutic agents available for clinical use. The use of traditional chemotherapy and new immune checkpoints inhibitors (ICIs) directed at programmed cell-death protein 1 (PD-1) or its ligand has led to unprecedented survival benefits in selected patients with metastatic UC. Data show that anti-PD-1 ICIs are not only improving long-term clinical benefit, but also quality of life for patients in the second-line setting. In the front-line setting, regulatory agencies have restricted the indications of atezolizumab and pembrolizumab (both ICIs) to patients with PD-L1positivity with advanced UC and who are platinum-ineligible. Very recently, erdafitinib, a pan-FGFR inhibitor, has been granted accelerated approval by FDA for platinum-pretreated advanced metastatic UC with susceptible FGFR3 or FGFR2 genetic alterations. Enfortumab vedotin, an antibody-drug conjugate, have been granted breakthrough designation by the FDA for the treatment of metastatic UC. Here we review the clinical trial data that have established standard-of-care treatment for advanced-stage UC. In addition, mechanisms of resistance and biomarkers of response to platinum-based chemotherapies and immunotherapies are also discussed, along with the clinical benefits and limitations of these therapies.
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Alice Tzeng,C. Marcela Diaz-Montero,Patricia A. Rayman,Jin S. Kim,Paul G. Pavicic,James H. Finke,Pedro C. Barata,Marcelo Lamenza,Sarah Devonshire,Kim Schach,Hamid Emamekhoo,Marc S. Ernstoff,Christopher J. Hoimes,Brian I. Rini,Jorge A. Garcia,Timothy D. Gilligan,Moshe C. Ornstein,Petros Grivas

DOI: https://doi.org/10.1007/s11523-018-0595-9

2018-09-28

Targeted Oncology

Abstract:BackgroundThe identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions.ObjectiveWe assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor cells [MDSC]; cytotoxic T lymphocytes [CTL]) following ICI therapy and investigated whether these changes correlated with outcomes in patients with metastatic urothelial carcinoma (mUC).Patients and MethodsSerial peripheral blood samples were collected from ICI-treated mUC patients. Flow cytometry was used to quantify PD1/PDL1 expression on MDSC (CD33+HLADR−) and CTL (CD8+CD4−) from peripheral blood mononuclear cells. MDSC were grouped into monocytic (M)-MDSC (CD14+CD15−), polymorphonuclear (PMN)-MDSC (CD14−CD15+), and immature (I)-MDSC (CD14−CD15−). Mixed-model regression and Wilcoxon signed-rank or rank-sum tests were performed to assess post-ICI changes in immune biomarker expression and identify correlations between PD1/PDL1 expression and objective response to ICI.ResultsOf 41 ICI-treated patients, 26 received anti-PDL1 (23 atezolizumab/3 avelumab) and 15 received anti-PD1 (pembrolizumab) therapy. Based on available data, 27.5% had prior intravesical Bacillus Calmette–Guérin therapy, 42% had prior neoadjuvant chemotherapy, and 70% had prior cystectomy or nephroureterectomy. Successive doses of anti-PDL1 correlated with decreased percentage of PDL1+ (%PDL1+) M-MDSC, while doses of anti-PD1 correlated with decreased %PD1+ M- and I-MDSC. Although pre-treatment %PD1+ CTL did not predict response, a greater %PD1+ CTL within 9 weeks after ICI initiation correlated with objective response.ConclusionsTreatment with ICI correlated with distinct changes in PD1/PDL1-expressing peripheral immune cell subsets, which may predict objective response to ICI. Further studies are required to validate immune molecular expression as a prognostic and/or predictive biomarker for long-term outcomes in mUC.

oncology
New editors in Acta Radiologica and Acta Radiologica Open

A. Skjennald

DOI: https://doi.org/10.1177/0284185117733082

2017-09-21

Acta Radiologica

Abstract:Dr. Zackrisson obtained her medical degree at Lund University, Sweden in 1999 and her PhD degree in 2006 with her thesis ‘‘Breast cancer screening in an urban Swedish population. Aspects of non-attendance, interval cancers and over-diagnosis.’’ Her present position is Senior Lecturer in Radiology at Lund University and Senior Consultant at Skåne University Hospital. Dr. Zackrisson is the author of more than 80 scientific publications and is the principal tutor of several doctoral students and post docs.
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis

David E Hinojosa-Gonzalez,Gal Saffati,Gustavo Salgado-Garza,Sagar Patel,Shane Kronstedt,Jeffrey A Jones,Jennifer M Taylor,Aihua E Yen,Jeremy R Slawin

DOI: https://doi.org/10.1016/j.urolonc.2024.07.006

Abstract:Metastatic urothelial carcinoma (muC) has historically had few effective therapeutic options. Recently, immune checkpoint inhibitors (ICIs), were introduced as therapeutic options for cisplatin-ineligible patients, however, direct head-to-head trials comparing these treatments are lacking. To address this gap, this study employs a Bayesian framework to indirectly compare the performance of ICIs as first-line agents for muC. A systematic review was performed to identify randomized controlled trials evaluating different ICI for mUC. Data was inputted into Review Manager 5.4 for pairwise meta-analysis. Data was then used to build a network in R Studio. These networks were used to model 200,000 Markov Chains via MonteCarlo sampling. The results are expressed as hazard ratios (HR) with 95% credible intervals (CrI). Six studies with 5,449 patients were included, 3,255 received ICI monotherapy or combination. Moreover, a total of 3,006 had PD-L1 positive tumors and 2,362 were PD-L1 negative. Median overall survival (OS) ranged from 12.1 to 31.5 months across the studies, with the combination of enfortumab vedotin and pembrolizumab demonstrating the most substantial reduction in the risk of death (HR 0.47 [95% CrI: 0.38, 0.58]), followed by avelumab monotherapy (HR 0.69 [95% CrI: 0.56, 0.86]). The limitations of this network meta-analysis include variability in study follow-up duration, lack of standardized methods for assessing PD-L1 positivity, and potential bias introduced by control arms with poorer survival outcomes across included trials. The enfortumab vedotin/pembrolizumab combination significantly improved survival and response rates. Avelumab showed notable single-agent activity. These findings provide a valuable framework to guide clinical decision-making and highlight priority areas for future research, including biomarker refinement and novel combination strategies to enhance antitumor immunity in this challenging malignancy.
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors

Maria Lucia Iacovino,Chiara Carmen Miceli,Marco De Felice,Biagio Barone,Luca Pompella,Francesco Chiancone,Erika Di Zazzo,Giuseppe Tirino,Carminia Maria Della Corte,Ciro Imbimbo,Ferdinando De Vita,Felice Crocetto

DOI: https://doi.org/10.3390/ijms23031133

IF: 5.6

2022-01-20

International Journal of Molecular Sciences

Abstract:Muscle invasive bladder cancer (MIBC) is a widespread malignancy with a worse prognosis often related to a late diagnosis. For early-stage MIBC pts, a multidisciplinary approach is mandatory to evaluate the timing of neoadjuvant chemotherapy (NAC) and surgery. The current standard therapy is platinum-based NAC (MVAC-methotrexate, vinblastine, doxorubicin, and cisplatin or Platinum–Gemcitabine regimens) followed by radical cystectomy (RC) with lymphadenectomy. However, preliminary data from Vesper trial highlighted that dose-dense NAC MVAC is endowed with a good pathological response but shows low tolerability. In the last few years, translational-based research approaches have identified several candidate biomarkers of NAC esponsiveness, such as ERCC2, ERBB2, or DNA damage response (DDR) gene alterations. Moreover, the recent consensus MIBC molecular classification identified six molecular subtypes, characterized by different sensitivity to chemo- or targeted or immunotherapy, that could open a novel procedure for patient selection and also for neoadjuvant therapies. The Italian PURE-01 phase II Trial extended data on efficacy and resistance to Immune Checkpoint Inhibitors (ICIs) in this setting. In this review, we summarize the most relevant literature data supporting NAC use in MIBC, focusing on novel therapeutic strategies such as immunotherapy, considering the better patient stratification and selection emerging from novel molecular classification.

biochemistry & molecular biology,chemistry, multidisciplinary
Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma

Mengnan Qu,Li Zhou,Xieqiao Yan,Siming Li,Xiaowen Wu,Huayan Xu,Juan Li,Jun Guo,Xu Zhang,Hongzhao Li,Xinan Sheng

DOI: https://doi.org/10.14440/bladder.2023.871

2023-12-11

Abstract:Urothelial carcinoma (UC) represents a common malignancy of the urinary system that can involve the kidneys, ureter, bladder, and urethra. Advanced/metastatic UC (mUC) tends to have a poor prognosis. UC ranks third in terms of human epidermal growth factor receptor 2 (HER2) overexpression among all tumors. However, multiple studies found that, unlike breast cancer, variable degrees of HER2 positivity and poor consistency between HER2 protein overexpression and gene amplification have been found. Trials involving trastuzumab, pertuzumab, lapatinib, afatinib, and neratinib have failed to prove their beneficial effect in patients with HER2-positive mUC, and a clinical trial on T-DM1 (trastuzumab emtansine) was terminated prematurely because of the adverse reactions. However, a phase II trial showed that RC48-ADC was effective. In this review, we provided an in-depth overview of the advances in the research regarding HER2-targeted therapy and the role of HER2 in mUC. Furthermore, we also discussed the prospects of potential strategies aimed at overcoming anti-HER2 resistance, and summarize the novel anti-HER2 approaches for the management of mUC used in recent clinical trials.
Systemic treatments for metastatic urothelial carcinoma

Aly-Khan A Lalani,Guru P Sonpavde

DOI: https://doi.org/10.1080/14656566.2018.1544242

Abstract:Introduction: Urothelial carcinoma is one of the most common cancers in the western world and, until recently, had limited therapeutic options. The contemporary advancement of immune checkpoint inhibitors (ICI) has heralded a new era for these patients and represents a major shift in the evolving treatment landscape. Areas covered: This article provides a comprehensive summary of the currently available treatments for metastatic urothelial carcinoma (mUC). The authors also review ongoing, phase-III studies with novel therapeutic targets and highlight recent insights into tumor biology that may help better understand the disease. Expert opinion: The treatment landscape for first-line therapy of mUC continues to include platinum-based chemotherapy for patients who are eligible. While the approval of ICI has changed the management in those who are post-platinum or platinum-ineligible, the wider use of ICI in the first-line setting requires further clarity given recent FDA announcements. Maintaining the remarkable progress in mUC may depend upon ongoing phase-III studies evaluating treatment options beyond ICI. Better prognostication and identification of those unlikely to respond to ICI remain important unanswered questions, particularly as this class of agents moves further along the disease spectrum of non-metastatic UC.
A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines

Dixita M. Patel,Ruba Mateen,Noor Qaddour,Alessandra Carrillo,Claire Verschraegen,Yuanquan Yang,Zihai Li,Debasish Sundi,Amir Mortazavi,Katharine A. Collier

DOI: https://doi.org/10.3390/cancers16020335

2024-01-13

Cancers

Abstract:Urothelial cancer is an immune-responsive cancer, but only a subset of patients benefits from immune checkpoint inhibition. Currently, single-agent immune checkpoint inhibitors (ICIs) and the combination of pembrolizumab with the antibody–drug conjugate enfortumab vedotin are approved to treat patients with metastatic UC (mUC). Approval of first-line nivolumab in combination with gemcitabine and cisplatin is expected imminently. Many treatment approaches are being investigated to better harness the immune system to fight mUC. In this review, we summarize the landmark clinical trials of ICIs that led to their incorporation into the current standard of care for mUC. We further discuss recent and ongoing clinical trials in mUC, which are investigating ICIs in combination with other agents, including chemotherapy, antibody–drug conjugates, tyrosine kinase inhibitors, and novel antibodies. Lastly, we review novel approaches utilizing bispecific antibodies, cellular therapies, and vaccines. The landscape of immunotherapy for mUC is rapidly evolving and will hopefully lead to better outcomes for patients.

oncology
Molecular pathology of urothelial carcinoma

Antonio Lopez-Beltran,Alessia Cimadamore,Rodolfo Montironi,Liang Cheng

DOI: https://doi.org/10.1016/j.humpath.2021.04.001

IF: 3.526

2021-07-01

Human Pathology

Abstract:The current personalized oncology era has witnessed significant efforts to integrate clinical, pathological, and molecular classifications. The growing need for molecular biomarkers to feed personalized oncology, together with the unprecedented wealth of knowledge on the molecular basis of bladder cancer, has led to a novel approach to this disease, incorporating molecularly generated data in clinical practice for locally advanced or metastatic disease. Translational research allows better understanding of the early events in the development of urothelial carcinoma in the urinary bladder. Thus, mutations in the KMT2D and KDM6A chromatin modifying genes confer competitive advantages that drive cells to colonize larger regions of the urothelium. Additional mutations in TP53, PIK3CA, FGFR3, or RB1 genes then trigger the process of malignant transformation in the urothelium. In the current review, we provide an overview on what could be the expected transition from the morphology-based classification to a combined, molecularly enriched reporting of clinically meaningful parameters aiming to promote personalized oncology of urothelial carcinoma.

pathology
The emerging treatment landscape of advanced urothelial carcinoma

Luisa Cardenas,Pooya Dibajnia,Aly-Khan Lalani

DOI: https://doi.org/10.1097/SPC.0000000000000573

2021-12-01

Abstract:Purpose of review: Urothelial carcinoma (UC) is one of the most common malignancies in the Western world. Historically, patients with advanced disease have had a poor prognosis and progress within months of completing upfront platinum-based chemotherapy. In the last two years, the treatment landscape for metastatic UC (mUC) has significantly shifted with the emergence of contemporary immunotherapy and targeted agents. The purpose of this review is to highlight the current and emerging systemic treatment options for mUC of the bladder. Recent findings: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated activity in the postplatinum and platinum-ineligible settings. Additionally, they have become a standard maintenance treatment option after avelumab demonstrated increased overall survival in patients with stable disease or better after first line platinum-based chemotherapy. Novel targeted therapies and antibody-drug conjugates (ADCs) have been granted Food and Drug Administration approval for subsequent line therapy based on promising results in phase II and III trials. Summary: There has been a considerable increase in the variety of effective therapies for mUC, including the utility of ICIs, novel targeted agents, and ADCs. Platinum-based chemotherapy remains an effective first-line option. As the role of novel therapies continues to shift toward earlier in the disease course, there remains an important need to develop feasible, globally accessible predictive biomarkers that can aid in patient selection and inform sequencing of therapeutic options.

[Asynchronous left ventricular filling in patients with angina pectoris: assessment by multiple gated blood pool imaging].

[The benefit of pars plana vitrectomy for the resolution of complications of proliferative diabetic retinopathy].

Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

The evolving treatment landscape of metastatic urothelial cancer

CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).

[Modifications in cutaneous flora following chloramphenicol therapy].

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.

Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma

Patterns of differentiation between human local populations.

Management of metastatic bladder cancer

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

New editors in Acta Radiologica and Acta Radiologica Open

Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis

Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors

Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma

Systemic treatments for metastatic urothelial carcinoma

A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines

Molecular pathology of urothelial carcinoma

The emerging treatment landscape of advanced urothelial carcinoma